SAN FRANCISCO, January 12, 2026 — PVP Labs will present its lead investigational candidate, Taphalgin® (lumekefamide), a tetrapeptide analgesic platform, to institutional investors and strategic partners at the J.P. Morgan Healthcare Conference 2026 in San Francisco.
Company leadership will hold one-on-one meetings during the conference week to discuss partnership structures and development strategy for the program. The company states that Taphalgin®, which is investigational, is open to co-development, regional or global licensing, or full asset acquisition.
Program and Regulatory Status
The company describes lumekefamide, an investigational candidate, as acting through selective μ1-opioid receptor agonism combined with calcium-channel modulation.
In the United States, Taphalgin® is investigational and at the pre-IND stage; it is not FDA- or EMA-approved. The company states that a pre-IND meeting with the FDA has been completed. Outside the United States, the company states that Taphalgin was approved in 2022, indicated for acute postoperative and cancer-related pain. Development areas named by the company include acute and post-surgical pain, military trauma and veterinary use.
Investors and partners can reach the business development team at [email protected].
Source: PVP Labs press release, January 12, 2026 (Business Wire).
Important information
Taphalgin® (lumekefamide) is an investigational product. It has not been approved by the U.S. Food and Drug Administration or the European Medicines Agency, and its safety and efficacy have not been established for any use in these jurisdictions. This content is provided for scientific and informational purposes only. It is not medical advice, not an offer to sell, and not a solicitation of any product.
Any references to human exposure, clinical experience, or regulatory interactions relate only to non-U.S. markets or to preliminary development activities and do not imply U.S. FDA approval, U.S. safety, or U.S. efficacy.
This announcement contains forward-looking statements regarding PVP Labs’ development and partnering plans. Actual results may differ materially due to clinical, regulatory and business risks.
About PVP Labs
PVP Labs is a Singapore-based peptide biotechnology company developing peptide therapeutics across analgesia, antiviral and tissue-repair indications.
